- Home
- SBSI vs GYRE Comparison
SBSI vs GYRE Comparison
Compare SBSI & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBSI
- GYRE
- Stock Information
- Founded
- SBSI 1960
- GYRE 2002
- Country
- SBSI United States
- GYRE United States
- Employees
- SBSI N/A
- GYRE N/A
- Industry
- SBSI Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SBSI Finance
- GYRE Health Care
- Exchange
- SBSI Nasdaq
- GYRE Nasdaq
- Market Cap
- SBSI 874.1M
- GYRE 897.1M
- IPO Year
- SBSI N/A
- GYRE N/A
- Fundamental
- Price
- SBSI $30.90
- GYRE $7.49
- Analyst Decision
- SBSI Hold
- GYRE
- Analyst Count
- SBSI 2
- GYRE 0
- Target Price
- SBSI $37.00
- GYRE N/A
- AVG Volume (30 Days)
- SBSI 120.6K
- GYRE 189.9K
- Earning Date
- SBSI 07-25-2025
- GYRE 08-12-2025
- Dividend Yield
- SBSI 4.63%
- GYRE N/A
- EPS Growth
- SBSI 7.94
- GYRE N/A
- EPS
- SBSI 2.91
- GYRE 0.02
- Revenue
- SBSI $254,817,000.00
- GYRE $100,643,000.00
- Revenue This Year
- SBSI $10.28
- GYRE $21.04
- Revenue Next Year
- SBSI $5.20
- GYRE $89.64
- P/E Ratio
- SBSI $10.55
- GYRE $93.64
- Revenue Growth
- SBSI 6.49
- GYRE N/A
- 52 Week Low
- SBSI $25.85
- GYRE $6.11
- 52 Week High
- SBSI $38.00
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- SBSI 64.77
- GYRE 42.81
- Support Level
- SBSI $30.72
- GYRE $7.49
- Resistance Level
- SBSI $31.32
- GYRE $7.80
- Average True Range (ATR)
- SBSI 0.56
- GYRE 0.48
- MACD
- SBSI 0.16
- GYRE 0.07
- Stochastic Oscillator
- SBSI 84.67
- GYRE 40.48
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.